Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published:December 10, 2024 Post category:uncategorized A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like Pandemic-induced social isolation: Assessing its impact on older adults’ wellbeing April 29, 2024 Fluoride and sealants win against youth dental caries, a robust review informs US health policy November 8, 2023 Daytime eating shields night shift workers from heart risks April 14, 2025
Fluoride and sealants win against youth dental caries, a robust review informs US health policy November 8, 2023